Results 91 to 100 of about 140,297 (347)
Cleavable linkers in antibody–drug conjugates
Chemical Society Reviews, 2019 This tutorial review summarises the advances in the field of cleavable linker technologies for antibody–drug conjugates (ADCs).
Jonathan D. Bargh +3 more
openaire +4 more sources
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles [PDF]
, 2010 PEGylated gold nanoparticles are decorated with various amounts of human transferrin (Tf) to give a series of Tf-targeted particles with near-constant size and electrokinetic potential.
C. A. Alabi +22 more
core +2 more sources
Molecular Oncology, EarlyView.Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley +1 more source
Polysaccharide-based self-assembling nanohydrogels: An overview on 25-years research on pullulan [PDF]
, 2015 The aim of this overview is to review the evolution of the studies carried out, during more than 25 years, on nanohydrogels obtained by self-assembling of pullulan (PUL) using several hydrophobization strategies.
ALHAIQUE, Franco +4 more
core +1 more source
Review of Antibody-Drug Conjugates
The Korean Journal of Medicine, 2023 Antibody-drug conjugates (ADCs) are target-specific conjugates that consist of a monoclonal antibody connected to a cytotoxic payload using a stable linker. These conjugates combine the highly specific targeting ability and potent killing effect to accurately and efficiently eliminate cancer cells, which has ushered in a new era of targeted therapy ...
openaire +1 more source
Molecular Oncology, EarlyView.Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon +13 more
wiley +1 more source
Molecular Oncology, EarlyView.In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková +14 more
wiley +1 more source
Targeted drug conjugates in cancer therapy: Challenges and opportunities
Pharmaceutical Science AdvancesTraditional chemotherapy is often accompanied by off-target toxicity, resulting in adverse side effects and driving the development of targeted therapies.
Geng Jia, Yuqi Jiang, Xiaoyang Li
doaj +1 more source
Laboratory evaluation of a rapid IgG4 antibody test (BLF Rapid™) for bancroftian filariasis [PDF]
, 2018 At the end phase of the Global Programme to Eliminate Lymphatic Filariasis, antibody testing may have a role in decision-making for bancroftian filariasis–endemic areas.
Babu, Subash +7 more
core +2 more sources